Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (29)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Levine, O. S.
Right arrow Articles by Casar, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levine, O. S.
Right arrow Articles by Casar, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

American Journal of Epidemiology Vol. 137, No. 11: 1221-1228
Copyright © 1993 by The Johns Hopkins University School of Hygiene and Public Health

research-article

Cost-Benefit Analysis for the Use of Haemophilus influenzae Type b Conjugate Vaccine in Santiago, Chile

Orin S. Levine1,, Edith Ortiz1,2, Rodrigo Contreras1,2, Rosanna Lagos1,3, Pablo Vial4, Alfredo Misraji3, Catterine Ferreccio1,2, Consuelo Espinoza2, Leon Adlerstein3, Patricio Herrera3 and Carlos Casar3

1Center for Vaccine Development, University of Maryland Baltimore, MD
2The Ministry of Health Santiago, Chile
3Roberto del Rio Children's Hospdal Santiago, Chile
4Center for Medical Investigations, School of Medicine, Catholic University of Chile Santiago, Chile

Reprint requests to Dr. Orin S. Levine, Center for Vaccine Development, University of Maryland School of Medicine, 10 S Pine St, Baltimore, MD 21201.

Cost-benefit analyses can be integral to the evaluation of interventions in developing countries. The authors compare the potential benefits to the Chilean Ministry of Health, in terms of treatment costs averted, by prevention of Haemophllus influenzae type b (HIB) invasive disease, with the costs of adding HIB conjugate vacane to the diphtheria-tetanus-pet-tussis (DTP) immunization routinely administered to infants. In their basecase model, over a 10-year period (1991–2000), vaccination against HIB will prevent 1,229 cases of HIB invasive disease, includIng 713 cases of meningitis, 107 of whom would suffer severe, long-term sequelae, and between 29 and 116 deaths. Assuming a cost of US$1 for a full three-dose regimen of vaccine, the benefit/cost ratio of 1.66. with a net discounted savings of over $403,225, illustrates that HIB vaccine can be cost-beneficial. Sensitivity analyses which alter each of the variables in the analysis indicate that if the true Incidence of HIB disease is twice the published rate, then three doses of vaccine remains cost-beneficial at US$3.

cost benefit analysis; developing countries; Haemophilus influenzae; immunization; meningltis; primary prevention; vaccines


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
M. Machado, M. Iskedjian, and T. R Einarson
Quality Assessment of Published Health Economic Analyses from South America
Ann. Pharmacother., May 1, 2006; 40(5): 943 - 949.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
F. Zhou, K. M. Bisgard, H. R. Yusuf, R. R. Deuson, S. K. Bath, and T. V. Murphy
Impact of Universal Haemophilus influenzae Type b Vaccination Starting at 2 Months of Age in the United States: An Economic Analysis
Pediatrics, October 1, 2002; 110(4): 653 - 661.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
H. Peltola
Worldwide Haemophilus influenzae Type b Disease at the Beginning of the 21st Century: Global Analysis of the Disease Burden 25 Years after the Use of the Polysaccharide Vaccine and a Decade after the Advent of Conjugates
Clin. Microbiol. Rev., April 1, 2000; 13(2): 302 - 317.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.